Christopher Marai
Stock Analyst at Nomura
(2.44)
# 2,342
Out of 4,708 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $14.21 | +6,655.81% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $40.44 | -18.39% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $4.41 | +1,940.82% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $244.62 | -69.75% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $6.24 | +156.23% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $150.75 | +160.03% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.60 | +2,025.00% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $123.21 | +86.68% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $13.70 | -12.41% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $12.91 | +47.15% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.69 | +2,440.62% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $14.21
Upside: +6,655.81%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $40.44
Upside: -18.39%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $4.41
Upside: +1,940.82%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $244.62
Upside: -69.75%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $6.24
Upside: +156.23%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $150.75
Upside: +160.03%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.60
Upside: +2,025.00%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $123.21
Upside: +86.68%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $13.70
Upside: -12.41%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $12.91
Upside: +47.15%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.69
Upside: +2,440.62%